Recent Work
-
Alzheimer’s Drug Approved; USC Policy Experts Available to Discuss FDA Approval of Leqembi
For the first time in two decades, an Alzheimer’s drug has received full Food and Drug Administration (FDA) approval. USC Schaeffer Center experts are available to discuss this milestone and the challenges ahead.
Categorized in -
Overpayments to Medicare Advantage Plans Could Exceed $75 Billion in 2023, USC Schaeffer Center Research Finds
Overpayments to Medicare Advantage plans now exceed 20% annually, underscoring the urgent need for reform.
Categorized in -
Comparing Doctors to Peers Doesn’t Make Them Hate Their Jobs and May Improve Quality of Care
Researchers found that behavioral interventions aimed at improving performance can be designed to protect clinician job satisfaction and improve quality of care.
Categorized in -
Biosimilars Drug Market Isn’t Broken After All, USC Schaeffer Study Finds
Researchers looked at cancer therapy trastuzumab (Herceptin) and found biosimilars bring competition to the market, with prices declining by more than half for some versions.
Categorized in -
Biosimilar Drugs Underutilized Due to Commercial Insurance Restrictions
The first study to examine biosimilar drivers finds commercial insurers limit use in almost 20% of cases.
Categorized in